Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)
NCT ID: NCT04550962
Last Updated: 2025-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
376 participants
OBSERVATIONAL
2020-11-02
2026-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective of the study is to characterize patients initiating DUPIXENT for asthma in a real-world setting, with respect to their medical history, including asthma history and asthma treatment history, socio-demographic, biomarkers (including Fractional exhaled nitric oxide \[FeNO\]), and concomitant treatments for asthma.
Secondary Objectives:
The secondary objectives of the study are:
* To characterize real-world use patterns of DUPIXENT for asthma (eg, most commonly used regimens, reason for initiation of new asthma treatments, concomitant therapies, treatment durations, and reasons for discontinuation and/or switching)
* To assess the effectiveness of DUPIXENT in asthma patients in a real world setting (lung function improvement, exacerbation rate, asthma control)
* To assess comorbid type 2 conditions (atopic/allergic) and patterns of use and effects of treatment in comorbid conditions in asthma patients treated with Dupixent
* To collect data on HealthCare Resource Utilization (HCRU)
* To collect safety data on study participants in the real-world setting.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma
NCT02573233
Registry of Asthma Patients Initiating DUPIXENT®
NCT04287621
Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma
NCT03782532
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
NCT01312961
An Observational, Retrospective Multicentre Medical Record Review to Describe the Post-authorisation Early Clinical Experience of Dupilumab in the Treatment of Adult Severe Asthma
NCT06064526
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with asthma
Eligible participants are initiating treatment with Dupixent for asthma according to the prescribing information in effect in each country
Dupilumab SAR231893
Pharmaceutical form:solution Route of administration: subcutaneous
Dose regimen:
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dupilumab SAR231893
Pharmaceutical form:solution Route of administration: subcutaneous
Dose regimen:
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Sciences & Operations
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigational Site Number : 0320005
La Plata, Buenos Aires, Argentina
Investigational Site Number : 0320006
Villa Rosa, Buenos Aires, Argentina
Investigational Site Number : 0320001
Ciudad Autonoma Bs As, , Argentina
Investigational Site Number : 0320008
Ciudad Autonoma Buenos Aires, , Argentina
Investigational Site Number : 0320009
San Miguel de Tucumán, , Argentina
Investigational Site Number : 0320004
Santa Fe, , Argentina
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520002
Quillota, Región de Valparaíso, Chile
Investigational Site Number : 1700009
Barranquilla, , Colombia
Investigational Site Number : 1700004
Bogotá, , Colombia
Investigational Site Number : 1700003
Bucaramanga, , Colombia
Investigational Site Number : 3760008
Ashdod, , Israel
Investigational Site Number : 3760004
Ashkelon, , Israel
Investigational Site Number : 3760005
Jerusalem, , Israel
Investigational Site Number : 3760003
Jerusalem, , Israel
Investigational Site Number : 3760001
Kfar Saba, , Israel
Investigational Site Number : 3760006
Rehovot, , Israel
Investigational Site Number : 3760007
Tel Aviv, , Israel
Investigational Site Number : 4140001
Kuwait City, , Kuwait
Investigational Site Number : 4220002
Beirut, , Lebanon
Investigational Site Number : 4220001
Beirut, , Lebanon
Investigational Site Number : 4220003
El Achrafiyé, , Lebanon
Investigational Site Number : 4840003
Durango, , Mexico
Investigational Site Number : 6340001
Doha, , Qatar
Investigational Site Number : 6430005
Chelyabinsk, , Russia
Investigational Site Number : 6430007
Moscow, , Russia
Investigational Site Number : 6430004
Moscow, , Russia
Investigational Site Number : 6430006
Rostov-on-Don, , Russia
Investigational Site Number : 6430008
Saratov, , Russia
Investigational Site Number : 6430002
Stavropol, , Russia
Investigational Site Number : 6820005
Jeddah, , Saudi Arabia
Investigational Site Number : 6820004
Mecca, , Saudi Arabia
Investigational Site Number : 6820002
Riyadh, , Saudi Arabia
Investigational Site Number : 6820001
Riyadh, , Saudi Arabia
Investigational Site Number : 7020002
Singapore, , Singapore
Investigational Site Number : 7020001
Singapore, , Singapore
Investigational Site Number : 7840006
Abu Dhabi, , United Arab Emirates
Investigational Site Number : 7840007
Dubai, , United Arab Emirates
Investigational Site Number : 7840001
Dubai, , United Arab Emirates
Investigational Site Number : 7840004
Sharjah city, , United Arab Emirates
Investigational Site Number : 7840002
Sharjah city, , United Arab Emirates
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OBS16688
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.